Saby George, MD

Articles by Saby George, MD

Triplet Combination Strategies to Manage Metastatic HSPC

ByRobert Dreicer, MD, MS, FACP,Saby George, MD,Mark Scholz, MD

May 4th 2022

Looking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.

Genomic Testing Practices in Prostate Cancer

ByRobert Dreicer, MD, MS, FACP,Saby George, MD,Mark Scholz, MD

April 27th 2022

Expert perspectives on optimal genomic testing practices in patients with prostate cancer.

Novel Approaches to Optimizing Management of mHSPC

ByRobert Dreicer, MD, MS, FACP,Saby George, MD,Mark Scholz, MD

April 27th 2022

Discussion on the selection of therapy for a patient with metastatic HSPC in the context of available agents and FDA approvals.

Patient Scenario 2: Selecting Therapy for mHSPC

ByRobert Dreicer, MD, MS, FACP,Saby George, MD,Mark Scholz, MD

April 20th 2022

Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.

PSMA-Targeted Therapy for nmCRPC

ByRobert Dreicer, MD, MS, FACP,Saby George, MD,Mark Scholz, MD

April 20th 2022

A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.

AR Inhibitor Selection in Nonmetastatic Castration-Resistant Prostate Cancer

ByRobert Dreicer, MD, MS, FACP,Saby George, MD,Mark Scholz, MD

April 13th 2022

Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.

Patient Scenario 1: nmCRPC Identification and Work-up

ByRobert Dreicer, MD, MS, FACP,Saby George, MD,Mark Scholz, MD

April 13th 2022

Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.

ADT Therapy in Prostate Cancer: Agonists vs Antagonists

ByRobert Dreicer, MD, MS, FACP,Saby George, MD,Mark Scholz, MD

April 6th 2022

Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.

Overview on Androgen Deprivation Therapy in Prostate Cancer

ByRobert Dreicer, MD, MS, FACP,Saby George, MD,Mark Scholz, MD

April 6th 2022

A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.

Continuing Nivolumab After Progression Improves Survival in RCC

BySaby George, MD

June 23rd 2016

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.